These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21284352)

  • 1. It's official...but not infallible.
    Prescrire Int; 2010 Nov; 19(110):244. PubMed ID: 21284352
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HIV agents. Maraviroc in treatment-experienced PHAs.
    TreatmentUpdate; 2006; 18(4):5. PubMed ID: 17205654
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel HIV treatment approved.
    Groeschen HM
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-HIV agents. Maraviroc--absorption and drug-interaction issues.
    TreatmentUpdate; 2007; 19(3):5. PubMed ID: 17571441
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA advisory committee approves Selzentry.
    AIDS Patient Care STDS; 2009 Nov; 23(11):987. PubMed ID: 19938371
    [No Abstract]   [Full Text] [Related]  

  • 6. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-HIV agents. Maraviroc approved in Canada.
    TreatmentUpdate; 2007; 19(6):1-3. PubMed ID: 18041146
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment. Maraviroc dosing not effective in half of blacks.
    AIDS Policy Law; 2014 Oct; 29(11):1. PubMed ID: 25330547
    [No Abstract]   [Full Text] [Related]  

  • 10. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 11. Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
    AIDS Alert; 2009 Jan; 24(1):10-2. PubMed ID: 19209462
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-HIV agents. Maraviroc and resistance.
    TreatmentUpdate; 2007; 19(6):4-5. PubMed ID: 18041148
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Access to maraviroc.
    TreatmentUpdate; 2007; 19(3):5-6. PubMed ID: 17575574
    [No Abstract]   [Full Text] [Related]  

  • 14. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pretreated HIV patients profit from Maraviroc. Oral HIV fusion inhibitor opens new therapy chances].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():52-3. PubMed ID: 19024918
    [No Abstract]   [Full Text] [Related]  

  • 16. More data on maraviroc in treatment-experienced patients.
    AIDS Patient Care STDS; 2007 May; 21(5):366-7. PubMed ID: 17549810
    [No Abstract]   [Full Text] [Related]  

  • 17. Pivotal moments in HIV treatment: the 14th CROI.
    Laurence J
    AIDS Read; 2007 May; 17(5):239-40. PubMed ID: 17532657
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-HIV agents. New drugs--hope and a degree of caution.
    TreatmentUpdate; 2007; 19(6):9-10. PubMed ID: 18041153
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-HIV agents. Getting to know your co-receptors.
    TreatmentUpdate; 2007; 19(3):1-2. PubMed ID: 17571439
    [No Abstract]   [Full Text] [Related]  

  • 20. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
    Delobel P; Raymond S; Mavigner M; Cazabat M; Alvarez M; Marchou B; Massip P; Izopet J
    AIDS; 2010 Jun; 24(9):1382-4. PubMed ID: 20559045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.